Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 2 (2005), Issue 8 (August)

1. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.
   Eur J Neurol, 12(8): 649-56. [Abstract] [Full-text]
2. Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients.
   Eur J Neurol, 12(8): 625-31. [Abstract] [Full-text]
3. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference.
   Eur J Neurol, 12(8): 588-601. [Abstract] [Full-text]
4. Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients.
   J Neuroimmunol, 166(1): 197-201. [Abstract] [Full-text]
5. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
   J Neuroimmunol, 166(1): 180-8. [Abstract] [Full-text]
6. Hyaluronate receptor (CD44) and integrin alpha4 (CD49d) are up-regulated on T cells during MS relapses.
   J Neuroimmunol, 166(1): 189-92. [Abstract] [Full-text]
7. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population.
   J Neurogenet, 19(1): 25-38. [Abstract] [Full-text]
8. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain.
   Proc Natl Acad Sci U S A, 102(31): 11094-9. [Abstract] [Full-text]
9. Object strength--an accurate measure for small objects that is insensitive to partial volume effects.
   MAGMA, 18(3): 162-9. [Abstract] [Full-text]
10. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis.
    J Allergy Clin Immunol, 116(2): 453-9. [Abstract] [Full-text]
11. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.
    Lancet, 366(9485): 579-82. [Abstract] [Full-text]
12. Long time interval between multiple sclerosis onset and occurrence of primary Sjögren's syndrome in a woman treated with interferon-beta.
    Acta Neurol Scand, 112(3): 194-6. [Abstract] [Full-text]
13. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis.
    Scand J Immunol, 62(2): 176-82. [Abstract] [Full-text]
14. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry, 76(9): 1294-6. [Abstract] [Full-text]
15. Is inflammation important in early PPMS? a longitudinal MRI study.
    J Neurol Neurosurg Psychiatry, 76(9): 1255-8. [Abstract] [Full-text]
16. Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.
    J Med Chem, 48(17): 5412-4. [Abstract] [Full-text]
17. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
    Lancet Neurol, 4(9): 567-75. [Abstract] [Full-text]
18. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing.
    Lancet Neurol, 4(9): 556-66. [Abstract] [Full-text]
19. Tolerance induction by bone marrow transplantation in a multiple sclerosis model.
    Blood, 106(5): 1875-83. [Abstract] [Full-text]
20. Immunity to tetanus is protective against the development of multiple sclerosis.
    Med Hypotheses, 65(5): 966-9. [Abstract] [Full-text]
21. Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia.
    Neuroepidemiology, 25(3): 129-34. [Abstract] [Full-text]
22. A longitudinal fMRI study on motor activity in patients with multiple sclerosis.
    Brain, 128: 2146-53. [Abstract] [Full-text]

© 2004-2008 Multiple Sclerosis Research Today. All Rights Reserved.